Evaluation of Efficacy of Comprehensive Genomic Tumour Profiling (CGP) from Liquid And/or Tissue Biopsy in Patients with Locally Advanced And/or Metastatic Solid Cancer
The aims of this study are * to evaluate the efficacy of comprehensive genomic tumour profiling (CGP) from liquid and/or tissue biopsy in patients with locally advanced and/or metastatic solid cancer. * to evaluate and describe the impact of treatment decisions based on CGP on individual progression free survival in patients with locally advanced and/or metastatic solid cancer * to evaluate and describe similarities and differences between the treatment suggestions based on CGP/IHC (immuno-histochemistry) of tissue biopsy and liquid biopsy. In patients with locally advanced and/or metastatic carcinoma the primary efficacy objective of the study is, to observe and describe the PFS (progression-free survival) of the matched treatment compared to the PFS of the most recent therapy.
• Initial diagnosis of histologically confirmed locally advanced and/or metastatic solid cancer
• Radiologically confirmed progression under the most recent therapy
• No further evidence-based drug treatment is established, or no satisfactory alternative treatments are available for the locally advanced and/or metastasized carcinoma
• Further therapy is medically feasible
• ECOG (Eastern Cooperative Oncology Group) performance status 0-2
• Life expectancy of at least 12 weeks
• Written informed consent and willingness to cooperate during the course of the study
• Capability to understand the intention and the consequences of the study